Science & Medicine
Home | Current Issue | Archives | Subscriptions | Contact Us

Log In | Search | Author Index | Advertising

HLA class I antigen loss in cancer

Daniel J. Hicklin, Soldano Ferrone
From: Science & Medicine: Volume 8 Number 2: Page 86 (April 2002)

View Full TextAdd To BasketPurchase Images

Abstract: Despite impressive results in animal models, T cell-based immunotherapy for human cancers has had only limited success. One important reason is the loss or down-regulation of antigen processing and presentation by HLA class I molecules, termed "HLA class I antigen loss." After an initial response to immunotherapy, tumor cells escape killing by cytotoxic T lymphocytes targeted to specific tumor antigens, and through immune selection, recurrent tumors often show progressive loss of HLA class I molecules. Identification of patterns of antigen loss may allow immunotherapy to be tailored to counteract these tumor cell defects.

Back to Table of Contents



Science & Medicine, Inc.
P.O. Box 313, Narberth, PA 19072
(610) 660-8097       (800) 888-0028
fax (610) 660-0348
e-mail editor@sciandmed.com
See our other journal: Medical Problems of Performing Artists.
Home | Current Issue | Archives | Subscriptions | Contact Us

Log In | Search | Author Index | Advertising

Copyright © 2002-2019, Science & Medicine, Inc.

Powered by Pliner Solutions, Inc.
Web Development by Pliner Solutions, Inc.